ImmunoGen Stock News

AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading price. The acquisition provides AbbVie with a commercial-stage company and a flagship drug that generated $10

From a technical perspective, ImmunoGen (IMGN) is looking like an interesting pick, as it just reached a key level of support. IMGN recently overtook the 20-day moving average, and this suggests a sho

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

Shares of ImmunoGen Inc (NASDAQ: IMGN) close to doubled this morning after AbbVie Inc (NYSE: ABBV) said it will buy the cancer therapies company for $10.1 billion. ImmunoGen stock priced at a massive

The Dow is sprinting to the finish line this November, ahead of a historically bullish month.

Other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.

ImmunoGen (IMGN) shares skyrocketed over 80% in early trading Thursday after AbbVie (ABBV) agreed to buy the rival biotech firm for $10.1 billion to expand its cancer drug portfolio.

ImmunoGen (NASDAQ: IMGN ) stock is seeing massive gains on Thursday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). A press release from AbbVie reveals that ImmunoGen is bei

AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share.

AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market for cancer treatments.

AbbVie Inc. ABBV, +0.30% announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN, +0.50% in a cash deal valued at $10.1 billion. Under terms of the agreement, AbbVie will

TM, PAY, WRB, MNDY and IMGN have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2023.

ImmunoGen, Inc. expects to convert the Accelerated Approval of its drug Elahere to "Full Approval" in the 1st half of 2024. Potential European approval of Elahere for treatment of patients with FRa-hi

The mean of analysts' price targets for ImmunoGen (IMGN) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.